Document:

Exhibit 10.1

 

Execution Version

 

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT
AGREEMENT

 

This AMENDED AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of April 21, 2020, between iBio, Inc.,
a Delaware corporation (the “Company”), and Thomas F. Isett, an individual resident of the State of Maryland
(“Executive”). This Agreement amends and restates in its entirety that certain Executive Employment Agreement,
dated March 10, 2020, between the Company and the Executive (the “Original Agreement”). The Company and Executive,
intending to be legally bound, agree as follows:

 

1.             Representations and Warranties. Executive represents and warrants to the Company that (a) he is not bound by any restrictive
covenants and has no prior or other obligations or commitments of any kind (written, oral or otherwise) that would in any way prevent,
restrict, hinder or interfere with Executive’s acceptance of employment with the Company or the performance of all duties
and services hereunder to the fullest extent of Executive’s ability and knowledge; (b) he has full power and capacity to
execute and deliver, and to perform all of his obligations under, this Agreement; and (c) this Agreement is binding upon and enforceable
against Executive. The Company represents and warrants to Executive that (x) the Company has full power and capacity to execute
and deliver, and to perform all of its obligations under, this Agreement; (y) the Company has obtained all approvals, consents,
and authorizations required by the Company in order to enter into and perform its obligations under this Agreement; and (z) this
Agreement is binding upon and enforceable against the Company.

 

2.             Duties. Executive will have the titles of Chief Executive Officer and Executive Co-Chairman of the Board, and shall be responsible
for all day to day management and operation of the business of the Company and such other duties and responsibilities as may be
assigned, from time to time, by and subject to the direction of the Company’s Board of Directors (the “Board”).
During the Term (as defined below), excluding any periods of vacation or sick leave to which Executive is entitled, (i) Executive
will apply on a full-time basis all of his skill and experience to the performance of his duties, and (ii) Executive will devote
as much time to the management of the business and affairs of the Company as is necessary for the proper conduct of the business
and affairs of the Company. Executive may, upon approval by the Board, engage in certain limited non-competitive activities, and
in charitable and civic activities. Executive will perform his duties under this Agreement with fidelity and loyalty, to the best
of his ability, experience and talent and in a manner consistent with his duties and responsibilities and in accord with best practices
within the Company’s industry.

 

3.             Employment Term. Unless earlier terminated as provided herein, the initial term of this Agreement will be for a period of
three (3) years, commencing on the date of the Original Agreement (the “Initial Term”); provided that thereafter
this Agreement will be extended for additional one (1) year periods unless, no later than sixty (60) days prior to the expiration
of the Initial Term or any such one (1) year extension period, as the case may be, either the Company or Executive provides notice
to the other of its intent to terminate this Agreement upon the completion of the Initial Term or any such one (1) year extension
period (the period of Executive’s employment by the Company under this Agreement will be referred to as the “Term”).

 

4.             Compensation. In exchange for services rendered by Executive hereunder, the Company will provide Executive with the following
compensation and benefits during the Term:

 

(a)           Base Salary. The Company will pay Executive a base salary at the annual rate of $490,000 (“Base Salary”),
with annual increases (effective July 1 of each fiscal year of the Company beginning in 2021) to be mutually agreed upon by Executive
and the Board not later than July 31 of each fiscal year of the Company. All Base Salary payments will be paid in the same manner
and at the same time as salary payments are made to other employees of the Company. Executive’s Base Salary and other compensation
paid to him from the Company (including all cash bonuses and severance payments) will be subject to such withholdings as may be
required by law.

 

     

    
Execution Version

    

 

(b)           Signing Bonus. Upon the full execution and delivery of the Original Agreement by both parties, Executive was entitled to
be paid a signing bonus in the amount of $450,000 in cash. Executive will be paid an additional signing bonus in the amount of
$250,000 in cash on the first anniversary of the Original Agreement, provided Executive is then employed with the Company (and,
as of such date, has not given notice of resignation or been provided with written notice of termination for Cause).

 

(c)           Annual Bonuses. For the Company’s fiscal year beginning July 1, 2019 and ending June 30, 2020, Executive will be paid
a guaranteed bonus in the amount of $80,000, which bonus amount will be paid in cash on July 1, 2020. For all fiscal years beginning
on or after July 1, 2020, Executive will be eligible for an incentive bonus (an “Incentive Bonus”) of up to
60% of his Base Salary. On or before July 31 of each Company fiscal year the Board and Executive shall determine mutually agreeable
performance criteria by which the Incentive Bonus for such fiscal year shall be earned.

 

(d)           Performance Bonus. Executive will be awarded a cash bonus in the amount of 4.5% of the transaction consideration paid in
connection with the consummation of a Change of Control Transaction during the Term; provided that such Change of Control Transaction
results in the stockholders of the Company receiving (or being entitled to receive, whether upon the consummation of the Change
of Control Transaction or at a future date) transaction consideration worth at least 120% of the average closing trading price
of the Company’s securities during the 20 trading-day period immediately preceding the consummation of the Change of Control
Transaction. For the purposes of this paragraph, “transaction consideration” means an amount of cash and the fair market
value of stock, equity, securities or other property paid or set aside for payment to the stockholders of the Company in connection
with the Change of Control Transaction. In addition “transaction consideration” includes all contingent, conditional
or deferred consideration paid or payable in connection with the Change of Control Transactions. The bonus paid pursuant to this
paragraph is subject to such withholdings as may be required by law and will be paid within 10 days after the date of the consummation
of the Change of Control Transaction.

 

(e)           Equity Grant. Within 90 days after the date of the Original Agreement, the Company will grant to Executive an option to
purchase 975,000 shares of the Company’s common stock (the “Option”), which will be issued to Executive
pursuant to the Company’ 2018 Omnibus Equity Incentive Plan and a Stock Option Award Agreement . The exercise price for such
Option shall be the fair market value on the date of grant, as determined by the Board. The Option will vest ratably over the 36-month
period beginning on the date of the Original Agreement (1/36 th per month) and will be deemed fully-vested upon any transaction
or series of related transactions that constitutes a Change of Control Transaction (as defined below).

 

(f)            Benefits. Executive will be offered the opportunity to participate in such medical and other employee benefit plans for
which he is eligible as may be established from time to time by the Company for other executive employees; provided, that the Company
shall pay the full cost of all medical, vision, and dental benefits provided to Executive and his family.

 

(g)           Holidays and Vacation. Executive will be entitled to be paid for holidays according to Company policy in effect from time
to time. Four (4) weeks of vacation will be taken at such times and dates as will not interfere with his duties and responsibilities
to the Company.

 

(h)           Car allowance. The Company will reimburse Executive on a monthly basis for all costs related to the use of one personal
vehicle for business purposes (including maintenance and fuel costs), which reimbursement will not exceed $750 per month.

 

    2

    
Execution Version

    

(i)            Continuing Education. The Company will pay for all continuing education expenses incurred by Executive up to a maximum of
$7,500 per year. Executive’s time spent in attendance at any continuing education will not be considered vacation time.

 

(j)            Relocation Assistance. If the duties of the Executive require the Executive to relocate his primary resident to any state
in which the Company maintains a physical office location, the Executive will notify the Board that he is required to relocate
his primary residence, and the Board will approve of such relocation (such approval not to be unreasonably withheld). In connection
with any such relocation, the Company will reimburse Executive for all reasonable and documented relocation expenses incurred by
Executive and the members of his immediate household in moving to the new location, including, without limitation, moving expenses,
rental payments for temporary living quarters in the area of relocation for a period not to exceed six months, real estate brokerage
commissions incurred by Executive in connection with the sale of his then existing primary residence, and loan financing charges
and closing costs incurred in connection with the acquisition and financing of a new residence. The Executive shall provide all
such expense reimbursement documentation within seventy-five (75) days of incurring such expense and the Company shall reimburse
the Executive within thirty (30) days thereafter.

 

(k)           Expense Reimbursement. While Executive is employed by the Company hereunder, the Company will reimburse Executive for all
reasonable and necessary out-of-pocket business, travel and entertainment expenses incurred by Executive in the performance of
the duties and responsibilities under this Agreement. Executive will provide additional documentation in the form of receipts,
vouchers, invoices and the like that pertain to and further substantiate and verify any such reimbursable expense, and the receipt
thereof by the Company, when requested, will be a condition precedent to payment. The Executive shall provide all such expense
reimbursement documentation within seventy-five (75) days of incurring such expense and the Company shall reimburse the Executive
within thirty (30) days thereafter.

 

5.             Termination. Executive and the Company acknowledge that Executive’s employment with the Company is at-will, which
may be terminated by the Company or Executive at any time for any reason or no reason. The provisions of Section 4(a) through
and including Section 4(e) govern the amount of compensation, if any, to be provided to Executive upon termination of employment
and do not alter this at-will status.

 

		(a)	Termination for Cause.

 

(i)            The
Company shall have the right to terminate Executive’s employment with the Company at any time for “Cause”,
which shall include, but is not limited to, the following:

 

(A)          Executive
is convicted of or Executive pleads guilty or nolo contendere to, any felony, or Executive is convicted of, or Executive
pleads guilty or nolo contendere to, any crime or offense (whether or not involving the Company or any of its affiliates)
either (A) constituting a crime of moral turpitude that is punishable by imprisonment in a state or federal correction facility,
or (B) involving acts of theft, fraud or embezzlement;

 

(B)           Executive’s
misconduct that causes material harm to the Company’s business reputation, or commission of a material act of dishonesty
involving the Company or its affiliates;

 

(C)           Material fraud with respect to the Company or any of its affiliates;

 

(D)          a
material breach by Executive of his obligations under this Agreement or any other written agreement with the Company, which Executive
fails to cure within 30 days after receipt of written notice of such breach; and

 

(E)           breach of the Company’s policies or procedures which causes, or could reasonably be expected to cause, material harm to
the Company or its affiliates, which Executive fails to cure within 30 days after receipt of written notice of such breach.

 

    3

    
Execution Version

    

 

(ii)           If the Company terminates Executive’s employment for Cause at any time, then: (A) Executive will not be entitled to pay
in lieu of notice or any other such compensation, and all compensation and benefits payable to Executive under this Agreement
terminate on Executive’s date of termination, and (B) the Company agrees to pay Executive the Base Salary and benefits under
Section 4(a) and Section 4(e) that have accrued as of the date of such termination.

 

		(b)	Termination Without Cause, for Disability or Voluntary Termination.

 

(i)            Executive’s employment hereunder may be terminated either by the Company without Cause or due to the Executive’s
disability (as defined below) or by Executive, in which event Executive will be entitled to receive his Base Salary for each day
following notice of such termination that Executive reports and is available for work until the termination date. As a professional
courtesy, the Company requests that Executive provide it with ninety (90) days’ written notice of his intent to terminate
employment pursuant to this Section 5(b). Likewise, where feasible, the Company will endeavor to provide Executive with
reasonable notice if it chooses to terminate the employment relationship. During any such notice period, Executive agrees to supply
any such transition services as the Board may direct. The Board, in its sole discretion, may direct Executive to not report to
his office and/or to not perform any services for the Company during such 90-day period.

 

(ii)           If the Company should terminate Executive’s employment for reasons other than for Cause or due to disability, subject
to the Executive’s execution of a release in form attached hereto as Exhibit A, the Company agrees to pay Executive
the Base Salary under Section 4(a), any accrued bonus under Section 4(c), and any benefits under Section 4(e)
and Section 4(f), for a period equal to the lesser of 24 months after termination or the remaining balance of the Term (collectively,
the “Severance Payments”), paid in accordance with the Company’s standard payroll schedule and practices.

 

		(c)	Death or Disability.

 

(i)            This
Agreement will terminate immediately upon Executive’s death, and the Company will not have any further liability or obligation
to Executive, Executive’s executors, heirs, assigns or any other person claiming under or through Executive’s estate,
except that Executive’s estate will receive any accrued but unpaid Base Salary, any accrued but unpaid bonus amounts, and
all benefits through the date of death.

 

(ii)           The
Company will have the right to terminate this Agreement if Executive becomes disabled. The term “disabled” means any
disability that qualifies as a disability under any long-term disability plan of the Company then in effect or, absent such a
plan, Executive’s inability, due to physical or mental ill health, to perform substantially all of the duties prescribed
to him in the context of Executive’s employment, on a full time basis and in a professional, competent, and consistent manner,
for one hundred twenty (120) days during any one hundred eighty (180) day period irrespective of whether or not such days are
consecutive.

 

(d)   Change of Control Transaction. Notwithstanding any provision of this Section 5 to the contrary, if the Company (or
its successor) terminates the employment of Executive upon or at any time in connection with a change in the ownership or effective
control of the Company or a change in the ownership of a substantial portion of the Company’s assets, each within the meaning
of Section 409A (as defined below (each, a “Change of Control Transaction”)), subject to the Executive’s
execution of a release in the form of Exhibit A attached hereto, the Executive shall be entitled to the following severance
payments and benefits upon such termination: (i) a lump sum cash payment, within 30 days after termination, equal to 24 months
of the Executive’s then-current base salary; (ii) a lump sum cash payment, within 30 days after termination, equal to a pro-rated
amount of his/her target annual bonus for the year immediately preceding the termination; (iii) payment of the full amount of all
premiums for continued health benefits (including COBRA) under the Company’s health plans for a period of 12 months following
the termination; and (iv) immediate vesting of 100% of the then-unvested portion of any outstanding equity awards held by the Executive.
In each case such amounts shall be less payroll taxes and withholding required by any federal, state or local law.

 

    4

    
Execution Version

    

 

6.             Non-Disclosure of Confidential Information. Executive acknowledges and agrees that, during the Term, he may have access
to and become familiar with various trade secrets and other confidential or proprietary information of the Company including, but
not limited to, the Company’s existing and contemplated services and products, documentation, technical data, contracts,
business and financial methods, practices and plans, costs and pricing, lists of the Company’s customers, prospective customers
and contacts, suppliers, vendors, consultants and employees, methods of obtaining customers, suppliers, vendors, consultants and
employees, financial and operational data of the Company’s present and prospective customers, suppliers, vendors, consultants
and employees and the particular business requirements of the Company’s present and prospective customers, suppliers, vendors,
consultants and employees, marketing and sales literature, records, software, diagrams, source code, object code, product development,
trade secrets; and the Company’s techniques of doing business, business strategies and standards (including all non-public
information of the Company, collectively, the “Confidential Information”). Executive expressly agrees not to
disclose any Confidential Information, directly or indirectly, nor use Confidential Information in any way, either during the Term
or at any time thereafter, except as required in the course of his employment with the Company. Specifically, during the Term or
engagement of Executive by the Company and thereafter, Executive (i) shall maintain the Confidential Information in strict confidence;
(ii) shall not disclose any Confidential Information to any person or other entity; (iii) shall not use any Confidential Information
to the detriment of the Company and for the benefit of Executive or any other person or entity; (iv) shall not authorize or permit
such use or disclosure; and (v) shall comply with the policies and procedures of the Company regarding use and disclosure of Confidential
Information. All files, papers, records, documents, drawings, specifications, equipment and similar items relating to the business
of the Company and Confidential Information, whether prepared by Executive or otherwise coming into his possession, shall at all
times remain the exclusive property of the Company and such items and all copies thereof shall be returned to the Company at Company’s
request or upon the expiration or termination of Executive’s employment. In connection with his termination of employment
with the Company, Executive will cooperate with the Company in completing and signing a termination statement or affidavit in the
form proscribed by the Company, which will contain Executive’s certification that he has no tangible Confidential Information
in his possession.

 

7.             Ownership
of Intellectual Property. To the extent that Executive, alone or with others, develops, makes, conceives, contributes to or
reduces to practice any intellectual property related to the duties of Executive hereunder or which results in any way from Executive
using the resources of the Company, during the period of Executive’s employment with the Company, whether or not during
working hours, such intellectual property is and shall be the sole and exclusive property of the Company.

 

To the extent any such
intellectual property can be protected by copyright, and is deemed in any way to fall within the definition of “work made
for hire” as such term is defined in 17 U.S.C. §101, such intellectual property shall be considered to have been produced
under contract for the Company as a work made for hire. In any event, and regardless of whether such intellectual property is deemed
to be a “work made for hire”, Executive shall disclose any and all such intellectual property to the Company and does
hereby assign to the Company any and all right, title and interest which Executive may have in and to such intellectual property.
Upon the Company’s request at any time, including any time after termination of Executive’s employment, Executive shall
execute and deliver to the Company such other documents as the Company deems necessary to vest in the Company the sole ownership
of and exclusive worldwide rights in and to, all of such intellectual property.

 

8.             Miscellaneous.

 

(a)           Notices.
All notices under this Agreement shall be sent and deemed duly given when posted in the United States first-class mail, postage
prepaid to the addresses set forth below such party’s signature on the signature page of this Agreement. These addresses
may be changed from time to time by written notice to the appropriate party. For the avoidance of doubt, no notice provided by
Executive to himself as an officer or employee of the Company will be effective to provide notice to the Company, and no notice
from Executive as an officer or employee of the Company to himself under this Agreement will be effective to provide notice to
Executive.

 

(b)           Assignment. This Agreement is binding upon the Company and Executive and may not be assigned by either of them without the
prior written consent of the other party.

 

    5

    
Execution Version

    

 

(c)           No Waiver. The failure of either the Company or Executive to object to any conduct or violation of any of the covenants
made by the other under this Agreement will not be deemed a waiver of any rights or remedies. No waiver of any right or remedy
arising under this Agreement will be valid unless set forth in an appropriate writing signed by both the Company and Executive.

 

(d)           Entire Agreement. This Agreement constitutes the entire understanding between the Company and Executive, and supersedes
all prior oral or written communications, proposals, representations, warranties, covenants, understandings or agreements between
the Company and Executive, relating to the subject matter of this Agreement, including the Original Agreement.

 

(e)           No Oral Modifications. No alterations, amendments, changes or additions to this Agreement will be binding upon either the
Company or Executive unless reduced to writing and signed by both the Company (by an officer specifically designated in writing
by the Board) and Executive.

 

(f)            Severability. The covenants, provisions and sections of this Agreement are severable, and if any portion of this Agreement
is held to be unlawful or unenforceable, the same will not affect any other portion of this Agreement, and the remaining terms
and conditions or portions thereof will remain in full force and effect. This Agreement will be construed in such case as if such
unlawful or unenforceable portion had never been contained in this Agreement, in order to effectuate the intentions of the Company
and Executive in executing this Agreement.

 

(g)           Survival. Provisions of this Agreement which by their nature are intended to survive termination of Executive’s employment
with the Company or expiration of this Agreement will survive any such termination or expiration of this Agreement, including but
not limited to Section 4 through and including Section 8.

 

(h)           Governing Law. This Agreement will be governed by and construed in accordance with the internal laws of the State of Delaware
without giving effect to the choice of laws principles thereof.

 

(i)            Jurisdiction;
Venue. Each of the parties hereto by its execution hereof:

 

(i)            irrevocably
submits to the jurisdiction of any state court located in the State of Delaware and to the jurisdiction of the United States District
Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based on this Agreement
or the subject matter hereof, and agrees that any state and federal court serving Wilmington, Delaware will be deemed to be a
convenient forum; and

 

(ii)           waives
to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any
such proceeding brought in any of the above-named courts, any claim that it is not subject personally to the jurisdiction of such
courts, that its property is exempt or immune from attachment or execution, that any such proceeding is brought in an inconvenient
forum, that the venue of such proceeding is improper, or that this Agreement, or the subject matter hereof, may not be enforced
in or by such court.

 

The parties
hereto hereby consent to service of process in any such proceeding in any manner permitted by the laws of the State of Delaware,
and agree that service of process by registered or certified mail, return receipt requested, at its address specified in or pursuant
to this Agreement is reasonably calculated to give actual notice.

 

(j)            Headings. The section headings of this Agreement are for convenience of reference only and shall not affect the construction
or interpretation of any of the provisions hereof.

 

(k)           Advice of Counsel and Construction. The parties acknowledge that all parties to this Agreement have been represented by
counsel, or had the opportunity to be represented by counsel of their choice. Accordingly, the rule of construction of contract
language against the drafting party is hereby waived by all parties.

 

    6

    
Execution Version

    

 

(l)            Counterparts; Electronic Signature. This Agreement may be executed in one or more counterparts, each of which will be deemed
an original, but all of which together will constitute one and the same instrument. Further, this Agreement may be executed by
transfer of an originally signed document by facsimile, e-mail or other electronic means, any of which will be as fully binding
as an original document.

 

(m)          Section 409A. Each payment under this Agreement, including each payment in a series of installment payments, is intended
to be a separate payment for purposes of Treas. Reg. §1.409A-2(b), and is intended to be: (i) exempt from Section 409A of
the Internal Revenue Code of 1986, as amended, the regulations and other binding guidance promulgated thereunder (“Section
409A”), including, but not limited to, by compliance with the short-term deferral exemption as specified in Treas. Reg.
 § 1.409A-1(b)(4) and the involuntary separation pay exception within the meaning of Treas. Reg. §1.409A-1(b)(9)(iii),
or (ii) in compliance with Section 409A, including, but not limited to, being paid pursuant to a fixed schedule or specified date
pursuant to Treas. Reg. § 1.409A-3(a) and the provisions of this Agreement will be administered, interpreted and construed
accordingly. If, nonetheless, this Agreement either fails to satisfy the requirements of Section 409A or is not exempt from the
application of Section 409A, then the parties hereby agree to amend or to clarify this Agreement in a timely manner so that this
Agreement either satisfies the requirements of Section 409A or is exempt from the application of Section 409A. Nevertheless, notwithstanding
any other provision of this Agreement to the contrary, none of the Company or any of its affiliates shall be directly or indirectly
liable for any failure of any payment made pursuant to this Agreement to comply with, or be exempt from, Section 409A.

 

 

(Signatures
on following page.)

 

 

    7

    
Execution Version

    

EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE
HAS CAREFULLY READ THIS AGREEMENT, HAS CONSULTED WITH AN ATTORNEY OF HIS CHOOSING TO THE EXTENT EXECUTIVE DESIRES LEGAL ADVICE
REGARDING THIS AGREEMENT, AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THE AGREEMENT.

 

 

IN WITNESS WHEREOF,
the parties hereto have each executed this Agreement effective as of the date first above written.

 

	COMPANY:	 	EXECUTIVE:
	 	 	 
	iBio, Inc.	 	 
	 	 	 
	 	 	 
	By: 	/s/ James T. Hill	 	 	/s/ Thomas
F. Isett	 
	Name:  James T. Hill	 	Thomas F. Isett, Individually
	Title:  Chair, Compensation Committee	 	 
	 	 	 
	 	 	 
	Address:	 	Address:
	 	 	 
	600 Madison Ave #1601	 	 	19 Sparks Farm Road	 
	New York, NY10022	 	 	Sparks, MD  21152	
	 	 	 	 	 
	 	 	 	 	 
	 	 	 
	with a copy to:	 	with a copy to:
	 	 	 
	Cohen & Buckmann	 	 	Miles & Stockbridge	 
	200 Park Avenue – Suite 1700	 	 	100 Light Street	 
	New York, New York 10166	 	 	Baltimore, MD  21202	 
	Attention: Sandra Cohen	 	 	Attention:
    Joseph Ward	 

  

    1

     

    

 

Exhibit
A

 

Form of
Waiver and Release

 

Pursuant to that certain
Amended and Restated Executive Employment Agreement, dated as of April 20, 2020 (the “Employment Agreement”
between iBio, Inc., a Delaware corporation (the “Company”) and me, and in consideration of the payments and
other benefits to be made to me (the “Benefits”) pursuant to the Employment Agreement, which were offered to
me in exchange for my agreement, among other things, to waive all of my claims against and release Company from any and all claims,
demands, actions, liabilities and damages arising out of or relating in any way to my employment with or separation from the Company;
provided, however, that this Waiver and Release will not apply to any claim or cause of action to enforce or interpret any provision
contained in the Employment Agreement.

 

I understand that
signing this Waiver and Release is an important legal act. I acknowledge that the Company has advised me in writing to consult
an attorney before signing this Waiver and Release and has given me at least 45 days from the day I received a copy of this Waiver
and Release to sign it.

 

In exchange for the
payment to me of Benefits, I, among other things, (1) agree not to sue in any local, state and/or federal court regarding or relating
in any way to my employment with or separation from the Company, and (2) knowingly and voluntarily waive all claims and release
the Company from any and all claims, demands, actions, liabilities, and damages, whether known or unknown, arising out of or relating
in any way to my employment with or separation from the Company, except to the extent that my rights are vested under the terms
of employee benefit plans sponsored by the Company and except with respect to such rights or claims as may arise after the date
this Waiver and Release is executed. This Waiver and Release includes, but is not limited to, claims and causes of action under:
Title VII of the Civil Rights Act of 1964, as amended; the Age Discrimination in Employment Act of 1967, as amended, including
the Older Workers Benefit Protection Act of 1990; the Civil Rights Act of 1866, as amended; the Civil Rights Act of 1991; the Americans
with Disabilities Act of 1990; the Energy Reorganization Act, as amended, 42 U.S.C. §§ 5851; the Workers Adjustment and
Retraining Notification Act of 1988; the Sarbanes-Oxley Act of 2002; the Employee Retirement Income Security Act of 1974, as amended;
the Family and Medical Leave Act of 1993; the Fair Labor Standards Act; the Occupational Safety and Health Act; claims in connection
with workers’ compensation or “whistle blower” statutes; and/or contract, tort, defamation, slander, wrongful
termination or any other state or federal regulatory, statutory or common law. Further, I expressly represent that no promise or
agreement which is not expressed in the Employment Agreement has been made to me in executing this Waiver and Release, and that
I am relying on my own judgment in executing this Waiver and Release, and that I am not relying on any statement or representation
of the Company. I agree that this Waiver and Release is valid, fair, adequate and reasonable, is entered into with my full knowledge
and consent, was not procured through fraud, duress or mistake and has not had the effect of misleading, misinforming or failing
to inform me.

 

Notwithstanding the
foregoing, nothing contained in this Waiver and Release is intended to prohibit or restrict me in any way from (1) bringing a lawsuit
against the Company to enforce the Company’s obligations under the Employment Agreement; (2) making any disclosure of information
required by law; (3) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought
by, any federal regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company’s
legal, compliance or human resources officers; (4) testifying or participating in or otherwise assisting in a proceeding relating
to an alleged violation of any federal, state or municipal law relating to fraud or any rule or regulation of the Securities and
Exchange Commission or any self-regulatory organization; or (5) filing any claims that are not permitted to be waived or released
under applicable law (although my ability to recover damages or other relief is still waived and released to the extent permitted
by law).

 

    2

     

    

 

Should any of the provisions
set forth in this Waiver and Release be determined to be invalid by a court, agency or other tribunal of competent jurisdiction,
it is agreed that such determination shall not affect the enforceability of other provisions of this Waiver and Release. I acknowledge
that this Waiver and Release and the Employment Agreement set forth the entire understanding and agreement between me and the Company
concerning the subject matter of this Waiver and Release and supersede any prior or contemporaneous oral and/or written agreements
or representations, if any, between me and the Company. I understand that for a period of 7 calendar days following the date
that I sign this Waiver and Release, I may revoke my acceptance of the offer, provided that my written statement of revocation
is received on or before that seventh day by [the following information is to be inserted at the time of termination of execution
of this Release:] [Name], [Title], [Company] [Address, City, State ZIP], in which case the Waiver and Release will not become
effective. In the event I revoke my acceptance of this offer, the Company shall have no obligation to provide me Benefits. I understand
that failure to revoke my acceptance of the offer within 7 calendar days from the date I sign this Waiver and Release will result
in this Waiver and Release being permanent and irrevocable.

 

I acknowledge that
I have read this Waiver and Release, have had an opportunity to ask questions and have it explained to me and that I understand
that this Waiver and Release will have the effect of knowingly and voluntarily waiving any action I might pursue, including breach
of contract, personal injury, retaliation, discrimination on the basis of race, age, sex, national origin, or disability and any
other claims arising prior to the date of this Waiver and Release. By execution of this document, I do not waive or release or
otherwise relinquish any legal rights I may have which are attributable to or arise out of acts, omissions, or events of the Company
which occur after the date of the execution of this Waiver and Release.

 

 

	 	 	 	 
	Employee’s Printed Name	 	Company Representative	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	Employee’s Signature	 	Company’s Execution Date	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	Employee’s Signature Date	 	Employee’s Social Security Number	 

 

    3EX-10.1

 Exhibit 10.1 

FIFTH AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT 

THIS FIFTH AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is entered into as of April 22,
2020 among AMVAC CHEMICAL CORPORATION, a California corporation (the “Company”), AMVAC NETHERLANDS B.V., a besloten vennootschap met beperkte aansprakelijkheid, organized under the law of the Netherlands (“AMVAC
Netherlands”), AMVAC C.V., a commanditaire vennootschap, organized under the law of the Netherlands (collectively, with AMVAC Netherlands, the “Designated Borrowers”), AMERICAN VANGUARD CORPORATION, a Delaware corporation
(“American Vanguard”), GEMCHEM, INC., a California corporation (“GemChem”), 2110 DAVIE CORPORATION, a California corporation (“2110 Davie”), AVD INTERNATIONAL LLC, a Delaware limited liability
company (collectively, with the Designated Borrowers, American Vanguard, GemChem and 2110 Davie, the “Guarantors”), the Lenders party hereto, and BANK OF THE WEST, as Agent. 

RECITALS 
 A.
Pursuant to a Second Amended and Restated Credit Agreement dated as of June 17, 2013 (as amended by a First Amendment dated as of July 11, 2014, a Second Amendment dated as of April 14, 2015, a Third Amendment dated as of
June 30, 2017 and a Fourth Amendment dated as of November 27, 2019, the “Credit Agreement”) among the Company, the Guarantors, the Designated Borrowers, the Lenders party thereto and the Agent, the Lenders extended and
agreed to extend credit to the Borrowers. Capitalized terms used herein which are not otherwise defined shall have the meanings given them in the Credit Agreement. 

B. The Company, the Guarantors and the Lenders have agreed to amend certain terms of the Credit Agreement as further provided in this
Amendment. 
 NOW, THEREFORE, in consideration of the above Recitals and for other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 AGREEMENT 

1. Amendments. On the Amendment Effective Date (as defined in Section 2 below), immediately after giving
effect to, and in reliance on the representations and warranties of the Borrowers set forth herein: 
 (a) Applicable Rate. The grid
contained in the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement is amended and restated in its entirety to read as follows: 

 

															
	 Applicable Rate
	 
	 Pricing
Level
	  	 Consolidated Funded Debt Ratio
	  	Unused
Fee	 	 	Eurocurrency Rate+
Daily One-Month LIBOR +
Standby Letter of Credit 
Fees	 	 	Alternate
Base Rate +	 
	 I
	  	3 3.50 to 1.00	  	 	0.35	% 	 	 	2.50	% 	 	 	1.50	% 
	 II
	  	<3.50 to 1.00 but 33.00 to 1.00	  	 	0.30	% 	 	 	2.25	% 	 	 	1.25	% 
	 III
	  	<3.00 to 1.00 but 32.25 to 1.00	  	 	0.25	% 	 	 	2.00	% 	 	 	1.00	% 
	 IV
	  	<2.25 to 1.00 but 3 1.50 to 1.00	  	 	0.20	% 	 	 	1.75	% 	 	 	0.75	% 
	 V
	  	<1.50 to 1.00	  	 	0.15	% 	 	 	1.50	% 	 	 	0.50	% 

  
 -1- 

 (b) The proviso at the end of the definition of “Eurocurrency Rate” in
Section 1.01 of the Credit Agreement is amended and restated in its entirety to read as follows: 
 provided that:
(i) to the extent a comparable or successor rate is approved by Agent in connection herewith, the approved rate shall be applied in a manner consistent with market practice; provided, further that to the extent such market practice is not
administratively feasible for Agent, such approved rate shall be applied in a manner as otherwise reasonably determined by Agent and (ii) if the Eurocurrency Rate shall be less than 0.50%, such rate shall be deemed to be 0.50% percent for
purposes of this Agreement. 
 (c) Permitted Acquisitions. Clauses (e), (f) and (g) in the definition of “Permitted
Acquisitions” in Section 1.01 of the Credit Agreement is amended and restated in its entirety to read as follow: 

(e) If the aggregate Acquisition Consideration for such Acquisition and all other Acquisitions made during the 90 days prior to such
Acquisition is equal to or greater than $15,000,000, the Consolidated Funded Debt Ratio, determined on a Pro Forma Basis after giving effect to such Acquisition, is not greater than the Adjusted Consolidated Funded Debt Ratio. As used in this
Agreement, “Adjusted Consolidated Funded Debt Ratio” means the ratio required by Section 8.08(a) after giving effect to an Acquisition reduced by 0.25 to 1.00; 

(f) If the aggregate Acquisition Consideration for such Acquisition and all other Acquisitions made during the 90 days prior to such
Acquisition is equal to or greater than $15,000,000, at least 10 days prior to American Vanguard or any of its Subsidiaries making such Acquisition, the Company shall have delivered or cause to be delivered to Agent a Compliance Certificate prepared
on a Pro Forma Basis and projections, each in form and substance satisfactory to Agent, demonstrating that, after giving effect to such Acquisition, (i) the Consolidated Funded Debt Ratio is not greater than the Adjusted Consolidated Funded
Debt Ratio required by clause (e) of this definition and (ii) no Event of Default will have occurred or is reasonably expected to occur prior to final payment in full in cash of all Obligations under this Agreement and termination of the
Commitments of the Lenders; 
 (g) (i) If the Acquisition Consideration for such Acquisition is equal to or greater than $30,000,000 but not
greater than $50,000,000, the Agent shall have consented to such Acquisition in writing and (ii) if the Acquisition Consideration for such Acquisition is greater than $50,000,000, the Required Lenders shall have consented to such Acquisition in
writing. 
 (d) Fifth Amendment Effective Date. A new definition of “Fifth Amendment Effective Date” is added in correct
alphabetical order to Section 1.01 of the Credit Agreement to read as follows: 
 “Fifth Amendment
Effective Date” means April 22, 2020. 
 (e) Consolidated Funded Debt Ratio. Section 8.08(a)
of the Credit Agreement is amended and restated in its entirety to read as follows: 
 (a) Permit the Consolidated Funded
Debt Ratio as of the end of any fiscal quarter to exceed the ratio set forth below opposite such fiscal quarter: 
  

			
	 Fiscal quarter ending
	  	Ratio
	Fifth Amendment Effective Date through September 30, 2020	  	4.00 to 1.00
	December 31, 2020	  	3.75 to 1.00
	March 31, 2021	  	3.50 to 1.00
	Thereafter	  	3.25 to 1.00

 Notwithstanding the foregoing, upon the consummation of any one or more Acquisitions during any period of
consecutive ninety (90) days for an aggregate Acquisition Consideration equal to or greater than $15,000,000, from and including the fiscal quarter in which Acquisition(s) equal to or greater than $15,000,000 occurred until and including the
end of the following three fiscal quarters 

  
 -2- 

 
thereafter (the “Adjusted Covenant Period”), the maximum Consolidated Funded Debt Ratio shall be increased by 0.50 to 1.00 (the
“Step-Up”), but, in no event, to greater than 4.25 to 1.00, during the Adjusted Covenant Period; provided that the maximum Consolidated Funded Debt Ratio must return to the ratio otherwise
permitted by this Section for the fiscal quarter immediately following any Adjusted Covenant Period. 
 (f) Compliance Certificate.
The form of Compliance Certificate appearing as Exhibit D to the Credit Agreement is amended and restated in its entirety to read as set forth on Exhibit D to this Amendment. 

2. Conditions Precedent to Effectiveness. This Amendment shall be effective as of the date (the “Amendment Effective
Date”) when the Agent determines that the following conditions have been satisfied: 
 (a) Agent shall have received, by original or
electronic transmission (promptly followed by originals), executed counterparts of this Amendment from each of the Loan Parties and the Lenders. 

(b) Agent shall have received for the pro rata account each Lender executing this Amendment an amendment fee equal to 0.05% of its Applicable
Percentage of the Aggregate Commitments. 
 (c) all acts and conditions required to be done and performed and to have happened precedent to
the execution, delivery and performance of this Amendment and to constitute the same a legal, valid and binding obligation of the parties, enforceable in accordance with its terms shall have been done and performed and shall have happened in due and
strict compliance with all applicable laws; 
 (d) all documentation shall be reasonably satisfactory in form and substance to the Agent and
its counsel; 
 (e) any fees and expenses of counsel required by the Agent to be paid on or before the Amendment Effective Date shall have
been paid, 
 (f) there shall not have occurred and be continuing a Default or Event of Default; and 

(g) to the extent that any Borrower qualifies as a “legal entity customer” under 31 C.R.F. Section 1010.230 (the
“Beneficial Ownership Regulation”), the Borrower shall have delivered to each Lender that so requests a certification regarding beneficial ownership required by the Beneficial Ownership Regulation. 

3. Miscellaneous Provisions. 

(a) Representations and Warranties. Each Loan Party hereby represents and warrants to the Agent and each Lender that each of the
representations and warranties of the Company and each other Loan Party contained in Article VI of the Credit Agreement and in any other Loan Document shall be true and correct in all material respects on and as of the Amendment Effective Date,
except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date. 

(b) Ratification. The Credit Agreement and each of the other Loan Documents, as amended hereby, is hereby ratified and remains in full
force and effect. 
 (c) Confirmation. Each Loan Party hereby confirms and agrees that: 

(i) at the time of the entering into the Security Documents governed by Dutch law, it was their intention (and it is still their intention and
agreement) that any security right created under such Security Document was intended to secure the obligations as amended, novated, supplemented, 

  
 -3- 

 
extended, restated (however fundamentally and whether or not more onerously) or replaced and includes any change in the purpose of, any extension of or any increase in any facility or the
addition of any new facility under that Loan Document or other agreement or instrument of the Borrowers and the other obligors under the Loan Documents; 

(ii) any security right created under the Security Documents governed by Dutch law shall extend to, and shall secure, the liabilities and
obligations of the Loan Parties under the Credit Agreement as amended by and in accordance with the terms of this Amendment; and 
 (iii)
any amount owed by the Loan Parties under the Credit Agreement as amended by and in accordance with the terms of this Amendment are part of the definition of (a) “Secured Obligations” (as defined in the Security Documents governed by
Dutch law), (b) “Parallel Debt” (as defined in the Credit Agreement) and (c) “Corresponding Obligations” (as defined in the Credit Agreement); 

(d) Entire Agreement. This Amendment embodies the entire agreement and understanding between the parties hereto and supersedes all prior
agreements and understandings relating to the subject matter hereof and thereof. 
 (e) Governing Law. This Amendment shall be
governed by and construed in accordance with the laws of the State of California, without giving effect to choice of law rules. 
 (f)
Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same agreement and any of the parties hereto may execute this Amendment by signing any such counterpart. 

[Remainder of page intentionally left blank.] 

  
 -4- 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the
day and year first above written. 
  

			
	AMVAC CHEMICAL CORPORATION, as the Company

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-1- 

 
			
	AMERICAN VANGUARD CORPORATION, as a Guarantor

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	GEMCHEM, INC., as a Guarantor

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	2110 DAVIE CORPORATION, as a Guarantor

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	AVD INTERNATIONAL LLC, as a Guarantor

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	AMVAC NETHERLANDS B.V., as a Designated Borrower and as a Guarantor

 
			
	
	 
	Name:	 	A.P.M. de Jong
	Title:	 	Managing Director

 
			
	
	AMVAC C.V., as a Designated Borrower and as a Guarantor
	
	By: AMVAC Chemical Corporation, General Partner

  

			
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-2- 

 
			
	BANK OF THE WEST, as Agent
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	BANK OF THE WEST, as a Lender, L/C Issuer and Swing Line Lender

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-3- 

 
			
	BMO HARRIS FINANCING, INC., as Lender

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-4- 

 
			
	WELLS FARGO BANK, N.A., as Lender
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-5- 

 
			
	UMPQUA BANK, as Lender

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-6- 

 
			
	COMPEER FINANCIAL, PCA, as Lender

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-7- 

 
			
	GREENSTONE FARM CREDIT SERVICES, ACA, as Lender

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature Page to Fifth Amendment to Second Amended and Restated Credit Agreement 

  
 -S-8- 

 Certificate of Authorized Officer 

  
 -1- 

 CERTIFICATE OF AUTHORIZED OFFICER 

The undersigned hereby certifies to the Agent that (1) each of the Loan Parties has previously delivered to the Agent a true, correct and
complete copy of its Organization Documents (collectively, the “Delivered Organization Documents”), (2) since such delivery, there has been no change in the Delivered Organization Documents except for those changes attached, and no
such document has been repealed, revoked, rescinded or amended in any respect, and each remains in full force and effect, (3) each of the Loan Parties remains in good standing in the jurisdiction of its organization, (4) the resolutions
(the “Delivered Resolutions”) previously delivered to the Agent by the Loan Parties authorize the execution, delivery and performance of the foregoing Amendment, (5) the Delivered Resolutions authorize the Person(s) holding the
office(s) indicated above or, if none, the office(s) held by the Person(s) executing the foregoing (the “Authorized Executing Office”) to execute the foregoing on behalf of the respective Loan Parties, (6) each Person executing
the foregoing Amendment on behalf of a Loan Party has been duly elected and now holds the Authorized Executing Office set forth below his(her) name, and the signature set forth above is his(her) true signature, (7) the undersigned is authorized
to deliver this Certificate on behalf of each of the Loan Parties, and (8) the Agent may conclusively rely on this Certificate unless and until superseding documents shall be delivered to the Agent. 

 

			
	 
		
	Type/Print Name:	 	 

 Certificate of Authorized Officer 

  
 -1- 

 EXHIBIT D 

FORM OF COMPLIANCE CERTIFICATE 
 Financial
Statement Date: _____________________________________ 
  

	To:	 Bank of the West, as Agent 

Ladies and Gentlemen: 
 Reference is made to that
certain Second Amended and Restated Credit Agreement, dated as of June 17, 2013 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Agreement”; the terms defined
therein being used herein as therein defined), among AMVAC Chemical Corporation, a California corporation (the “Company”), the Designated Borrowers from time to time party thereto, the other Loan Parties and Lenders from time to time party
thereto, and Bank of the West, as Agent, L/C Issuer and Swing Line Lender. 
 The undersigned Responsible Officer hereby certifies as of the
date hereof that he/she is the _________________________________ of the Company, and that, as such, he/she is authorized to execute and deliver this Certificate to Agent on the behalf of the Company, and that: 

[Use following paragraph 1 for fiscal year-end financial statements] 

1. The Company has delivered the year-end audited financial statements required by
Section 6.01(a) of the Agreement for the fiscal year of American Vanguard ended, as of the above date, together with the report and opinion of an independent certified public accountant required by such section. 

[Use following paragraph 1 for fiscal quarter-end financial statements]

 1. The Company has delivered the unaudited financial statements required by Section 6.01(b) of the
Agreement for the fiscal quarter of the Company ended as of the above date. Such financial statements fairly present the financial condition, results of operations and cash flows of American Vanguard and its Subsidiaries in accordance with GAAP as
at such date and for such period, subject only to normal year-end audit adjustments and the absence of footnotes. 

2. The undersigned has reviewed and is familiar with the terms of the Agreement and has made, or has caused to be made under his/her
supervision, a detailed review of the transactions and condition (financial or otherwise) of American Vanguard and its Subsidiaries during the accounting period covered by such financial statements. 

3. A review of the activities of American Vanguard and its Subsidiaries during such fiscal period has been made under the supervision of the
undersigned with a view to determining whether during such fiscal period each of the Borrowers performed and observed all its Obligations under the Loan Documents, and 

[select one:] 

[to the best knowledge of the undersigned during such fiscal period each of the Borrowers performed and observed each covenant and
condition of the Loan Documents applicable to it, and no Default has occurred and is continuing.] 
 Form of Compliance Certificate 

  
 -1- 

 --or--

 [to the best knowledge of the undersigned, during such fiscal period the following covenants or conditions have not been
performed or observed and the following is a list of each such Default and its nature and status:] 
 4. The representations and
warranties of (i) the Loan Parties contained in Article VI of the Agreement and (ii) each Loan Party contained in each other Loan Documents or in any document furnished at any time under or in connection with the
Loan Documents, are true and correct on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date, and except that
for purposes of this Compliance Certificate, the representations and warranties contained in subsections (a) and (b) of Section 6.01 of the Agreement shall be deemed to refer to the most recent statements furnished
pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Agreement, including the statements in connection with which this Compliance Certificate is delivered. 

5. The financial covenant analyses and information set forth on Schedules 1 and 2 attached hereto are true
and accurate on and as of the date of this Certificate. 
 IN WITNESS WHEREOF, the undersigned has executed this Certificate as of
____________ ______, ______. 
  

			
	AMVAC CHEMICAL CORPORATION

 
			
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 Form of Compliance Certificate 

  
 -2- 

 SCHEDULE 1 

to the Compliance Certificate 

[attach financial statements] 

Schedule 1 to Form of Compliance Certificate 

  
 -1- 

 SCHEDULE 2 

to the Compliance Certificate 
 For the
Quarter/Year ended __________________________ (“Statement Date”) 
  

													
	 	  	 	 	  	 	  	 	  	($ in 000’s)	 
	I.	  	 	Section 8.08(a) — Consolidated Funded Debt Ratio	 
		  	 	A.	 	  	Consolidated Funded Indebtedness (incl. Letters of Credit, Capitalized Leases, Amounts Outstanding Under Product Acquisition Agreements, etc.)	  			
		  				  	1.	  	Consolidated Funded Indebtedness:	  	$	__________	 
		  	 	B.	 	  	Consolidated EBITDA for the four fiscal quarters just ended:	  			
		  				  	1.	  	Consolidated Net Income:	  	$	__________	 
		  				  	2.	  	Consolidated Interest Expense:	  	$	__________	 
		  				  	3.	  	Provision for taxes:	  	$	__________	 
		  				  	4.	  	Depreciation and amortization:	  	$	__________	 
		  				  	5.	  	Nonrecurring non-cash charges and up to $5,000,000 in related cash charges subject to consent of Agent:	  	$	__________	 
		  				  	6.	  	Losses (gains) on the sale of fixed assets:	  	$	__________	 
		  				  	7.	  	Non-cash stock based compensation expenses:	  	$	__________	 
		  				  	8.	  	Extraordinary losses (gains):	  	$	__________	 
		  				  	9.	  	Losses (gains) from Dispositions of assets and discontinued operations outside of the ordinary course of business:	  	$	__________	 
		  				  	10.	  	EBITDA subject to consent of Agent related to Acquisitions pursuant to Permitted Acquisitions under the Credit Agreement	  	$	__________	 
		  				  	11.	  	Consolidated EBITDA
(Sum of 1+2+3+4+5+/-6+7+/-8+/-9+10):	  	$	__________	 
		  	 	C.	 	  	Consolidated Funded Debt Ratio (Ratio of 1.A.1 to 1.B.11):	  			

 Not to exceed: 
  

			
	 Fiscal quarter ending
	  	
Ratio               
 

	Fifth Amendment Effective Date through September 30, 2020	  	4.00 to 1.00
	December 31, 2020	  	3.75 to 1.00
	March 31, 2001	  	3.50 to 1.00
	Thereafter	  	3.25 to 1.00

 (g) Notwithstanding the foregoing, upon the consummation of any one or more Acquisitions during any period
of consecutive ninety (90) days for an Acquisition Consideration of more than $15,000,000 until the end of the fourth full fiscal quarter after the last such Acquisition (the “Adjusted Covenant Period”), the maximum
Consolidated Funded Debt Ratio shall be increased by 0.50 to 1.00 (the “Step-Up”) but, in no event, to greater than 4.25 to 1.00, during the Adjusted Covenant Period; provided that the maximum
Consolidated Funded Debt Ratio must return to the ratio otherwise permitted by Section 8.08(a) for the fiscal quarter immediately following any Adjusted Covenant Period. 

Schedule 2 to Form of Compliance Certificate 

  
 -1- 

															
	Applicable Rate	 
	 Pricing
Level
	 	 Consolidated Funded Debt Ratio
	 	Unused
Fee	 	 	Eurocurrency Rate+
Daily One-Month LIBOR +
Standby Letter of Credit Fees	 	 	Alternate
Base Rate +	 
	I	 	3 3.50 to 1.00	 	 	0.35	% 	 	 	2.50	% 	 	 	1.50	% 
	II	 	<3.50 to 1.00 but 33.00 to 1.00	 	 	0.30	% 	 	 	2.25	% 	 	 	1.25	% 
	III	 	<3.00 to 1.00 but 32.25 to 1.00	 	 	0.25	% 	 	 	2.00	% 	 	 	1.00	% 
	IV	 	<2.25 to 1.00 but 3 1.50 to 1.00	 	 	0.20	% 	 	 	1.75	% 	 	 	0.75	% 
	V	 	<1.50 to 1.00	 	 	0.15	% 	 	 	1.50	% 	 	 	0.50	% 

 Applicable Rate based on prior Compliance Certificate: Level ___ 

Applicable Rate based on current Compliance Certificate: Level ___ 
  

													
	II.	  	 	Section 8.08(b) — Consolidated Fixed Charge Coverage Ratio	 
		  	 	A.	 	  	Adjusted Consolidated EBITDA:	  			
		  				  	1.	  	Consolidated EBITDA (I.B.11 above):	  	$	__________	 
		  				  	2.	  	Maintenance Capital Expenditures up to 2% of book value:	  	$	__________	 
		  				  	3.	  	Adjusted Consolidated EBITDA (1 minus 2):	  	$	__________	 
		  	 	B.	 	  	The sum of:	  			
		  				  	1.	  	Consolidated Interest Expense paid in cash:	  	$	__________	 
		  				  	2.	  	Principal payments paid or payable on Consolidated Funded Indebtedness (other than Loans and L/C Obligations):	  	$	__________	 
		  				  	3.	  	Federal, state, local and foreign income taxes paid in cash:	  	$	__________	 
		  				  	4.	  	Distributions made:	  	$	__________	 
		  				  	5.	  	Total (sum of 1+2+3+4):	  	$	__________	 
		  	 	C.	 	  	Ratio of II.A.3 to II.B.5:	  			
		  				  		  	  
	  
	 
		  				  	Not to be less than 1.25 to 1.00.	  			
	III.	  	 	Section 8.09 — Capital Expenditures	 
		  	 	A.	 	  	Capital Expenditures fiscal year to date:	  	$	__________	 
	Not to exceed $30,000,000 in any fiscal year plus not more than $10,000,000 carried over from the immediately preceding fiscal year.	 
		  	 	B.	 	  	Carried Over Capital Expenditures from prior fiscal year:	  	$	__________	 

 Schedule 2 to Form of Compliance Certificate 

  
 -2- 

											
	IV.	  	 	Section 7.14 — Material Subsidiaries	 
		  	 	A.	 	  	5% of consolidated net assets of American Vanguard:	  	$	__________	 
		  	 	B.	 	  	Consolidated net assets of Subsidiaries who were not Guarantors or Material Subsidiaries as of the end of the immediately preceding fiscal quarter:	  	$	__________	 
		  	 	C.	 	  	If B is greater than A, identity of Subsidiary (Subsidiaries) whose net assets increased (or which was acquired or created) and caused such excess:	  			
		  				  		  	  
	  
	 
		  	 	D.	 	  	10% of consolidated gross revenues of American Vanguard for 4 fiscal quarters most recently ended:	  	$	__________	 
		  	 	E.	 	  	Consolidated gross revenues of Subsidiaries who were not Guarantors for the 4 fiscal quarters most recently ended.	  	$	__________	 
		  	 	F.	 	  	If D is greater than E, identity of Subsidiary (Subsidiaries) whose gross revenues increased (or which was acquired or created) and caused such excess.	  			
		  				  		  	  
	  
	 
		  	 	G.	 	  	Subsidiary(ies) included in C and F that are not Guarantors:	  			
		  				  		  	  
	  
	 
		  	 	H.	 	  	Identity of any Subsidiary acquiring Equity Interests in Designated Borrower or Material Subsidiary during most recent fiscal quarter:	  			
		  				  		  	  
	  
	 
	
	Domestic Subsidiaries included in Line G are Material Domestic Subsidiaries. Material Domestic Subsidiaries and Domestic Subsidiaries holding Equity Interests in Material Subsidiaries (Line H) are required to be
Affiliate Domestic Guarantors.  
 Foreign Subsidiaries included in Line G are
Material Foreign Subsidiaries. Material Foreign Subsidiaries and Foreign Subsidiaries holding Equity Interests in Material Subsidiaries (Line H) are required to be Affiliate Foreign Guarantors.
	     
    

		
	V.	  	 	Section 8.05 – Investments	 
		  	 	A.	 	  	Acquisition Consideration for Acquisitions made after the Closing Date	  	$	_________	 
	Aggregate Acquisition Consideration for all Acquisitions made after the Closing Date not to exceed $225,000,000.	 
		  	 	B.	 	  	Consolidated outstanding investments of American Vanguard in Foreign Wholly-Owned Subsidiaries	  	$	_________	 
	Such Investments made after the Closing Date not to exceed $200,000,000.	 
		  	 	C.	 	  	Consolidated outstanding Investments of American Vanguard in Joint Ventures and other Investments	  	$	__________	 
	Such Investments made after the Closing Date not to exceed $30 Million	 

 Schedule 2 to Form of Compliance Certificate 

  
 -3- 

									
	 VI. Section 8.16—Distributions
	  			
		 	 A.
	  	Consolidated Net Income for 4 quarters ending with quarter prior to current quarter	  	$	__________	 
		 	 B.
	  	Dividends declared in current quarter for payment in subsequent quarter	  	$	__________	 
		 	 C.
	  	Cash dividends paid in current fiscal quarter and in two prior fiscal quarters	  	$	__________	 
		 	 D.
	  	Sum of VI.B. plus VI.C (not to exceed VI.A)	  	$	__________	 
	
	Cash dividends declared in any fiscal quarter and paid in subsequent fiscal quarter not to exceed, when aggregated with cash dividends paid or payable during the fiscal quarter in which such cash dividend is declared
and cash dividends paid during the two fiscal quarters prior to the quarter in which such declaration is paid, Consolidated Net Income for the four fiscal quarters ending prior to the fiscal quarter in which such cash dividends are
declared.	       

 Schedule 2 to Form of Compliance Certificate 

  
 -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]